Gossamer Bio (GOSS) Non Operating Interest Expenses (2019 - 2026)

Gossamer Bio has reported Non Operating Interest Expenses for 8 years, with the latest figure at $2.7 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 1.42% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 0.03% change from a year earlier, with the FY2025 full-year figure at $11.0 million, down 4.58% from the prior year.
• Non Operating Interest Expenses was $2.7 million for Q2 2026 at Gossamer Bio, down from $2.8 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $3.5 million in Q1 2023, with the low at $2.7 million in Q2 2026.
• Average Non Operating Interest Expenses over 5 years is $3.1 million, with a median of $3.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses retreated 29.98% in 2022, then increased 0.95% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $3.5 million in 2022, then declined by 6.31% to $3.2 million in 2023, then slipped by 15.47% to $2.7 million in 2024, then rose by 0.47% to $2.8 million in 2025, then declined by 1.67% to $2.7 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.7 million (Q2 2026), $2.8 million (Q1 2026), and $2.8 million (Q4 2025), per Business Quant data.